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Chemical agentsBurden of disease (BoD) studies aim to identify the public health impact of different health problems and risk
factors. To assess BoD, detailed knowledge is needed on epidemiology, disability and mortality in the popu-
lation under study. This is particularly challenging for foodborne disease, because of the multitude of causa-
tive agents and their health effects. The purpose of this study is to systematically review the methodology of
foodborne BoD studies. Three key questions were addressed: 1) which data sources and approaches were
used to assess mortality, morbidity and disability?, 2) which methodological choices were made to calculate
Disability Adjusted Life Years (DALY), and 3) were uncertainty analyses performed and if so, how? Studies
(1990–June 2012) in international peer-reviewed journals and grey literature were identified with main in-
clusion criteria being that the study assessed disability adjusted life years related to foodborne disease.
Twenty-four studies met our inclusion criteria. To assess incidence or prevalence of foodborne disease in
the population, four approaches could be distinguished, each using a different data source as a starting
point, namely 1) laboratory-confirmed cases, 2) cohort or cross-sectional data, 3) syndrome surveillance
data and 4) exposure data. Considerable variation existed in BoD methodology (e.g. disability weights,
discounting, age-weighting). Almost all studies analyzed the effect of uncertainty as a result of possible im-
precision in the parameter values. Awareness of epidemiological and methodological rigor between
foodborne BoD studies using the DALY approach is a critical priority for advancing burden of disease studies.
Harmonization of methodology that is used and of modeling techniques and high quality data can enlarge the
detection of real variation in DALY outcomes between pathogens, between populations or over time. This
harmonization can be achieved by identifying substantial data gaps and uncertainty and establish which se-
quelae of foodborne disease agents should be included in BoD calculations.
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Foodborne diseases encompass a wide spectrum of illnesses and
are a growing public health problem worldwide (Tauxe et al., 2010).
They are the result of ingesting contaminated foodstuffs, and range
from diseases caused by a multitude of microorganisms to those
caused by chemical hazards. The most common clinical presentation
of foodborne diseases results in gastrointestinal symptoms, but
foodborne diseases can also lead to chronic, life-threatening symp-
toms including neurological, gynecological or immunological disor-
ders as well as multi-organ failure, cancer and death (WHO, 2007).
The burden of disease concept provides a methodological frame-
work to quantify and compare the health of populations using the dis-
ability adjusted life year (DALY); a summary measure of population
health that includes the effects of mortality, morbidity and disability.
Morbidity here represents the presence of diseases and disability repre-
sents loss of function. A fundamental goal in assessing burden of disease
is to identify the relative magnitude of different health problems and
risk factors. This insight is significant for medical resource allocation
and for targeting and monitoring possible impact of interventions in
the food chain (Havelaar et al., 2007a; Mangen et al., 2010; Murray
and Lopez, 1996; Worldbank, 1993). In principle, burden of disease
analyses should provide DALY estimates based on the overall preva-
lence or incidence of morbidity and disabilities in the population. To
achieve this, detailed knowledge is needed on epidemiology and health
effects in the population under study (Anand and Hanson, 1997;
Murray and Acharya, 1997). For foodborne disease this is particularly
challenging, because of the multitude of causative agents and their
health effects and the potentially broad span of time between exposure
and symptoms. To deal with the lack of required epidemiological data
profound statistical modelling has to be applied to assess the impact
of foodborne disease on public health. In addition, the methodology
of the burden of disease assessments is complex, both in concept and
in application, and there are many methodological alternatives
which affect DALY estimates, e.g. using alternative life expectancies,
incidence- or prevalence-based estimates or alternative sets of dis-
ability weights.
1.1. Aim of this study
This systematic review aims to provide an overview of the
methodology of foodborne burden of disease studies using the DALY
approach. Three key questions were addressed: 1) which data sources
and approaches were used to assessmortality, morbidity and disability?,
2) which methodological choices were made to calculate DALYs, and
3) were uncertainty analyses performed and if so, how?
2. Methods
The Global Burden of Disease (GBD) 1996 study used the DALY to
estimate the total burden of disease worldwide as the sum of the bur-
den of all separate diseases (Murray and Lopez, 1996). After this land-
mark study, a number of global and national burden of disease studies
have been performed. The experiences of researchers involved in
these studies served as a basis for a practical guide on burden of dis-
ease studies published by the World Health Organization (WHO)
(Mathers et al., 2001). However, this practical guide does not addressspecific problems that arise when undertaking foodborne burden of
disease studies. This review aims to complement the practical guide
by collating the approaches of existing foodborne burden of disease
studies.
2.1. Selection criteria and definitions
The systematic review was restricted to burden of disease studies
relevant to foodborne disease. Foodborne diseases can be defined as
those conditions that are commonly transmitted through ingested
food. Foodborne diseases comprise a broad group of illnesses caused
by microbial pathogens, parasites, chemical contaminants and bio
toxins (WHO, 2008).
Empirical studies in international peer-reviewed journals and grey lit-
erature published in English in the period January 1990–June 2012 were
included. Grey literature is defined as any material not identifiable
through a traditional index or database, and includes for instance national
reports, theses and unpublished studies (McKimmie and Szurmak, 2002).
The reviewwas restricted to studies using the DALY as burden of disease
measure.
2.2. Disability adjusted life year
The DALY is calculated by adding the number of years of life lost
due to mortality (YLL) to time spent in less than perfect health due
to morbidity and disability, expressed in healthy year equivalents
lost to disability (YLD) (Murray and Acharya, 1997). YLL is calculated
by summation of the number of fatal cases (d) due to health outcome
h in a certain period multiplied by the residual expected life expec-
tancy (e) at the age of death:
YLL ¼ dhe ð1Þ
YLD is calculated by multiplying the number of incident cases
(Inc) at a certain age with health outcome h by the duration of the
health outcome (t) and the disability weight (dw) assigned to health
outcome h:
YLD ¼ Inchthdwh ð2Þ
If the prevalence-based approach is applied, than YLDprev is calcu-
lated by multiplying the number of prevalent cases (P) in age group
‘A’ at a point in the reference period with the disability weight (dw)
assigned to health outcome h:
YLDprevA ¼ PA  dwh ð3Þ
The basic formulae can be supplemented due to methodological
choices (e.g. expanding with a discount factor and applying age
weighting) (Murray, 1994).
2.3. Foodborne disease model
Burden of disease studies relevant to foodborne disease may be
subdivided into agent-based, outcome-based and risk factor-based
Fig. 1. Foodborne disease model.
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agent-based approach covers all relevant health outcomes that can
be attributed to one particular agent, including sequelae. A sequela
is a pathological condition resulting from a prior disease, injury, or
attack. The health outcomes may be subdivided in different disease
categories. With the agent-based approach, the starting point of the
burden of disease calculation is illness due to exposure to chemical
contaminants or bio toxins or infection in case of microbial patho-
gens or parasites. To assess the disease burden of an agent, the com-
plete disease burden that is attributable to this illness/infection is
added up (Havelaar et al., 2000, 2012; Kretzschmar et al., 2012; Van
Lier et al., 2007).
The outcome-based approach assigns thedisease burden to clinically
defined categories of diseases, irrespective of their cause (Kretzschmar
et al., 2012; Van Lier et al., 2007).
With the risk factor approach, the burden of disease is attributed
to health determinants and risk factors, such a unsafe water and lack
of sanitation and hygiene (Kay et al., 2000). A risk factor is an attri-
bute or exposure which is causally associated with an increased
probability of a disease or injury (Murray and Lopez, 1996). In case
of foodborne disease, a risk factor may affect exposure to agents
that cause foodborne illness. One can attribute an adverse health
outcome (e.g. disease case or fatality) to a single cause (causal attri-
bution) or to a group of (counterfactual analysis) (Maldonado and
Greenland, 2002).2.4. Data sources and search strategy
Searches of eligible studies were conducted in Medline (PubMed),
EMBASE andWeb of Science. Searches for eligible grey literature were
conducted in Google Scholar and SIGLE (System for Information on
Grey Literature in Europe).
All international peer-reviewed articles and grey literature pub-
lished in English in the period January 1990 to June 2012were included
in the searches.
Search terms used for burden of foodborne disease studies
were: ‘burden of disease’, ‘disability adjusted life year’, ‘DALY’,
‘foodborne diseases’, ‘parasite’, ‘diarrheal’ and ‘diarrhoeal’, ‘qual-
ity adjusted life years’, ‘disabled persons/statistics & numerical
data health status measure’, and ‘health status’, ‘cost of illness’,
‘morbidity’, ‘mortality’, ‘cohort studies’. Keywords were matched
to database specific search terms (e.g. Medical Subject Headings
(MeSH) terms).In addition to database searches, reference lists of review studies
and articles included in the review were screened for titles that
included key terms.
Studies were included in the review if they met the following
criteria:
– The subject of the study was burden of disease measurement of
foodborne diseases and presenting DALY estimates;
– The burden of disease study was a general multiple cause study or
specific burden of disease study relevant to foodborne disease;
– The articles were published in English.
2.5. Data extraction
Relevant papers were selected by screening the titles (first step),
abstracts (second step) and entire articles (third step), retrieved
through the database searches. During each step respectively the
title, abstract or entire article was screened to ensure that it met
the selection criteria listed above. This screening was conducted in-
dependently by two researchers (JH and SP). Disagreement about
eligibility between the reviewers was solved through discussion.
Full articles were critically appraised by two reviewers (JH and SP),
using data extraction forms, which included information on the study
population, details regarding the methods used to calculate YLL and
YLD, main conclusions etc. Their reports were compared and disagree-
ments were resolved by discussion.
3. Results
Fig. 2 shows the flow diagram of the search of existing burden of
disease studies and main reasons for exclusion. In total, 24 burden
of disease studies related to foodborne disease were found. Six of
these studies were global burden of disease studies (Fewtrell et al.,
2005, 2004; Furst et al., 2012; Guerrant et al., 2002; Mathers et al.,
2007; Pruss et al., 2002). Thirteen studies have been performed in Eu-
rope (Gkogka et al., 2011; Haagsma et al., 2008; Havelaar et al., 2000,
2012, 2007b, 2004, 2010; Kortbeek et al., 2009; Reij et al., 2009;
Torgerson et al., 2008; Valent et al., 2004; Van Lier et al., 2007;
Verhoef et al., 2012), and five studies were performed in Africa,
South East Asia and the Western Pacific (i.e. Cameroon, South Africa,
Bangladesh, Tibet, New Zealand). Table 1 shows the number of
foodborne burden of disease studies per WHO region, subdivided
into agent-based, outcome-based and risk-factor based approaches.
The majority of burden of disease studies relevant to foodborne
Fig. 2. Flow diagram of the search of existing burden of disease studies related to foodborne disease.
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Fewtrell et al., 2005, 2004; Furst et al., 2012; Gkogka et al., 2011;
Haagsma et al., 2008; Havelaar et al., 2000, 2012, 2007b, 2004;
Kortbeek et al., 2009; Lake et al., 2010; Lokuge et al., 2004; Praet et
al., 2009; Reij et al., 2009; Torgerson et al., 2008; Valent et al., 2004;
Van Lier et al., 2007; Verhoef et al., 2012)).
1) Which data sources were used to assess mortality, morbidity and
disability?
Table 2 presents a detailed overviewof the data used to calculate YLL
and YLD. It shows that oftenmore than one data source is needed to
assess incidence and prevalence regarding foodborne disease.
Data sources that were used to assess mortality to calculate YLL
comprised vital registration data, case fatality ratios derived from lit-
erature (e.g. outbreak studies), demographic information or a com-
bination of data sources. Seven studies reported that they corrected
for underreporting of death statistics, for instance by modelling the
proportion of undiagnosed cases (Budke et al., 2004) or by using
case fatality ratios rather than reported deaths or by combining
case fatality ratios and vital registration data (Gkogka et al., 2011;
Havelaar et al., 2000, 2012, 2004; Verhoef et al., 2012). Van Lier et
al. explored the effect of underreporting by scenario analysis (Van
Lier et al., 2007). In case of missing data, literature was used to de-
rive assumptions regarding the proportion and/or age distribution
of fatal cases (Reij et al., 2009). Verhoef et al. used the age distribu-
tion of fatal cases from another country as proxy (Verhoef et al.,
2012).To assess incidence or prevalence of morbidity and disability, four
approaches could be distinguished, each using a different data
source as a starting point, namely a) laboratory-confirmed cases,
b) cross-sectional data, c) syndrome surveillance or survey data
and d) exposure data. Fig. 3 shows a schematic representation of
the four approaches to estimate incidence.
a) From laboratory-confirmed cases to incidence
Six studies used laboratory-confirmed cases that were derived
from passive surveillance systems (Gkogka et al., 2011; Havelaar
et al., 2012; Lake et al., 2010; Torgerson et al., 2008; Van Lier et al.,
2007; Verhoef et al., 2012). Subsequently, most studies applied
scaling factors to estimate the total number of laboratory-
confirmed cases (i.e. accounting for underreporting), cases at-
tending a GP and the total number of cases in the populations
(i.e. accounting for underdiagnosis). The scaling factors are
based on surveys, expert opinion or assumptions.
Data-quality—The data quality is dependent on the test sensi-
tivity of the laboratory test used, the number of positive cases
that are reported and the coverage rate of the surveillance sys-
tem. The extrapolation of the laboratory confirmed cases is de-
pendent on the information that is available for the scaling
factors. One study did not extrapolate data (Van Lier et al.,
2007), which, as acknowledged by the authors, means that data
is restricted to cases reported in surveillance system, which
most probably results in underreporting and underestimation of
burden of disease. On the other hand, Gkogka et al. used multi-
pliers for underreporting that were derived from studies in
Table 1
Burden of disease studies relevant to foodborne disease (n = 24), subdivided into agent-based, outcome-based and risk-factor based approach.
Agent-based Studies
(na)
References WHO Region Specific agents
Enteric agents 9 Gkogka et al. (2011), Haagsma et al. (2008),
Havelaar et al. (2000, 2004, 2012), Lake et al.
(2010), Reij et al. (2009), Van Lier et al. (2007),
Verhoef et al. (2012)
EURO, WPRO Campylobacter spp., Salmonella spp., Enterohaemorrhagic
E. coli, Listeria monocytogenes, Yersinia enterocolitica,
norovirus, rotavirus, Shiga Toxin-Producing E. coli O157,
Staphylococcus aureus, Bacillus cereus, Clostridium perfringens,
Hepatitis A virus, Hepatitis E virus, Cronobacter spp.,
Clostridium botulinum, Brucella spp., Leptospira spp., Shigella spp.
Parasitic agents 8 Budke et al. (2004), Furst et al. (2012),
Gkogka et al. (2011), Havelaar et al. (2007b,
2012), Kortbeek et al. (2009), Praet et al.
(2009), Torgerson et al. (2008)
EURO, WPRO, AFRO, Global Toxoplasma gondii, Giardia lamblia, Cryptosporidium parvum,
Echinoccosis, Taenia solium, Entamoeba histolytica, Trematodes
Chemical agents 4 Fewtrell et al. (2005, 2004), Lokuge et al. (2004),
Valent et al. (2004)
SEARO, EURO, Global Lead, arsenicum
Outcome-based Specific outcomes
Communicable 2 Guerrant et al. (2002), Mathers et al. (2007) Global Diarrheal disease, tropical disease
Non-communicable 1 Nafar et al. (2008) EMRO Chronic kidney disease
Risk factor Specific risk factor
Environmental risk
factor
2 Lewin et al. (2007), Pruss et al. (2002) AFRO, WPRO, Global Unsafe water and lack of sanitation and hygiene
a Numbers add up to 26 studies, because Gkogka et al. (2011) and Havelaar et al. (2012) are included in two subgroups: enteric agents and parasitic agents.
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garding the comparability of multipliers and health care systems
of both countries. All studies that used laboratory-confirmed
data as a starting point reported that data on severity, sequelae
and excess mortality were not available.
b) From cohort data or cross-sectional data to incidence
Eight studies used cohort or cross-sectional data to estimate
incidence (Budke et al., 2004; Haagsma et al., 2008; Havelaar
et al., 2000, 2012, 2007b, 2004; Kortbeek et al., 2009;
Verhoef et al., 2012). With this approach, data derived from
a cohort or cross-sectional studies is used to calculate the
number of patients that are infected. The data may consist of
stool sample data (Haagsma et al., 2008; Havelaar et al.,
2012; Verhoef et al., 2012), seroprevalence data (Havelaar et
al., 2007b; Kortbeek et al., 2009) or ultrasound screening
data (Budke et al., 2004). The number of positive cases is ex-
trapolated to the whole population to assess incidence or
prevalence, depending on the nature of the disease that is in-
vestigated, using scaling factors. The scaling factors are based
on regional coverage and age composition of the cohort. If
this approach is used to estimate prevalence, then a subse-
quent step that may be taken is to assess incidence in the pop-
ulation based on the estimate of prevalence.
Data-quality—The data quality is dependent on sensitivity of
the tests used to assess the syndrome (e.g. abdominal ultra-
sound), the number and representativeness of the sample in-
cluded in the surveillance or survey, geographical aspects (Is
data collected in only a part of the region of study? Is this
part of the region representative for the whole region?), avail-
ability and quality of data on the association of the agent and
the syndrome and other aspects, such as stigmatization of
the disease of interest, which may affect participation and/or
reporting.
Information for the scaling factors may be very limited or
crude, which raises questions about the validity of the extrap-
olations. Specific problems were that for some studies (part
of) the cohort data was more than 10 years older than the
year(s) to which the burden of disease estimates pertained
to and that time-specific changes in infection rates were not
accounted for. Other problems with data quality were thatinformation on true positivity of cases, incidence and severity
of complications and/or sequelae were not available.
c) From syndrome surveillance or survey data to incidence
An important step of this approach is to assess the proportion
of the cases attributable to the agent. This step is not taken
with the approaches a and b. One study used survey data to
assess prevalence (Praet et al., 2009); these survey data
were extrapolated to the whole population to assess preva-
lence using scaling factors based on sample size and age com-
position of the cohort (Praet et al., 2009). The next step
assesses the proportion of cases attributable to the agent
and estimate incidence in the population.
Data quality: Issues with data quality are similar to those of
approach b. Specific problems that were encountered in the
study by Praet et al. were the high number of assumptions
(Praet et al., 2009), because data for a number of crucial aspects
of were not available (e.g. data on attribution, hospitalization,
outpatient treatment, cases in the population and mortality).
d) From exposure to incidence
Five studies started with exposure to assess incidence or preva-
lence (Fewtrell et al., 2005, 2004; Lokuge et al., 2004; Reij et al.,
2009; Valent et al., 2004). With this approach, regional exposure
data are used to calculate exposure levels of a population. Scal-
ing factors, based on sample size and age composition of the co-
hort, were applied to extrapolate exposure data to the whole
population. Subsequently, levels of exposure are used to calcu-
late the proportion of the population that is affected based on
dose–response information. The proportion of affected population
is then used to calculate prevalence or incidence in the population.
Data-quality—The data quality of the exposure data is highly de-
pendent on the availability, applicability and representativeness
of the population of such studies. The methods that are used for
sampling, measuring and reporting vary widely, impeding com-
parison and pooling of results. Quality of the methods and tech-
niques were highly dependent on the region. Data for certain
regionsweremissing and regional variationwas not taken into ac-
count. Apart from that, the studies frequently are unclear whether
samples were taken in rural or urban settings. Similarly to the ap-
proaches a, b and c, information for the scaling factorsmay be very
limited or very crude.
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YLL and YLD
General burden of disease methods
Table 3 presents a detailed overview of the methods used to calcu-
late YLL and YLD.
Incidence or prevalence-based approach—Whether an incidence
or prevalence-based approach is used is highly dependent on the
goal of the study. The incidence-based approach reflects the future
burden of disease based on current events, where all health out-
comes, including those in future years, are assigned to the initial
event. The prevalence-based approach reflects the current burden
of disease based on previous events. In practice, it is often difficult
to rigidly apply the incidence or prevalence-based approach and
sometimes compromises must be made. The majority (n = 21)
of burden of disease estimates were based on incidence data.
The year to which the data applied varied from 1990 through
2009. Some studies used an average of cases over several years
to calculate incidence to obtain a more stable estimate.
Age-weighting and discounting—With age-weighting the altering
levels of productivity and dependency with age are taken into ac-
count, meaning that years lived at youngest and oldest age are
given less weight, because at these ages a person is more depen-
dent on others. Age-weighting was performed in ten studies
(Budke et al., 2004; Fewtrell et al., 2004; Guerrant et al., 2002;
Lokuge et al., 2004; Mathers et al., 2007; Nafar et al., 2008; Praet
et al., 2009; Pruss et al., 2002; Torgerson et al., 2008; Valent et
al., 2004). Discounting reflects the economic concept that immedi-
ate profits are generally preferred over benefits later in time
(Murray and Lopez, 1996). When discounting is applied future
life years are assigned less value than those lived today. Seventeen
studies used a discount factor that varied between 1.5 and 4%
(Bhutta et al., 2011; Budke et al., 2004; Fewtrell et al., 2005;
Guerrant et al., 2002; Haagsma et al., 2008; Havelaar et al., 2000,
2012, 2007b, 2004; Lokuge et al., 2004; Mathers et al., 2007;
Nafar et al., 2008; Praet et al., 2009; Pruss et al., 2002; Torgerson
et al., 2008; Valent et al., 2004; Verhoef et al., 2012).
Methods to calculate YLL
Four studies did not calculate YLL, either because the health out-
come under study did not result in fatality (mild mental retarda-
tion due to exposure to lead (Fewtrell et al., 2004); skin lesions
due to exposure to arsenic (Valent et al., 2004)) or because YLL
from a previous burden of disease study was used (Guerrant et
al., 2002; Lewin et al., 2007).
The life expectancy that was used for the YLL calculations varied.
Eight studies used the global life table, i.e. the West Level 26 (for
women) and 25 (for men) life-tables, that were developed by
GBD (Budke et al., 2004; Havelaar et al., 2000, 2012; Mathers et
al., 2007; Praet et al., 2009; Pruss et al., 2002; Van Lier and
Havelaar, 2007; Verhoef et al., 2012). Country specific life expec-
tancy tables were also used by eight studies (Gkogka et al., 2011;
Haagsma et al., 2008; Havelaar et al., 2004; Kortbeek et al., 2009;
Lake et al., 2010; Nafar et al., 2008; Reij et al., 2009; Torgerson et
al., 2008).
Methods to calculate YLD
Disability weights—A crucial aspect to calculate YLD is the disabil-
ity weight; a value ranging from 1, indicating worst imaginable
health state equal to death, to 0, indicating full health. Its value
is based on the preferences of a panel of judges stated towards a
set of hypothetical health states, expressing the relative undesir-
ability of the health state (Drummond et al., 1997; Murray and
Acharya, 1997). Following the GBD 1996 study, for which a large
set of disability weights was derived (Murray and Lopez, 1996),
other sets of disability weights have been developed. Often used
alternative disability weights are the Dutch disability weights.
Several studies reported that there were no disability weights
available for particular health outcomes, such as human alveolarand cystic echinococcosis, foodborne trematodiasis and reactive
arthritis. In these cases, proxy-disability weights, i.e. disability
weights of health outcomes with similar health effects, were
used (Budke et al., 2004; Furst et al., 2012) or a set of disability
weights that was specifically derived for the study (Haagsma et
al., 2008; Havelaar et al., 2012).
Sequelae—A second aspect in the assessment of burden of disease
concerns the coverage of long-term health outcomes or sequelae.
A sequela is a pathological condition resulting from a prior disease,
injury, or attack. To satisfy the aspiration of an agent-based bur-
den of disease studies, all sequelae should be taken into account.
Most of the burden of foodborne disease studies (n = 14;(Budke
et al., 2004; Gkogka et al., 2011; Guerrant et al., 2002; Haagsma
et al., 2008; Havelaar et al., 2000, 2012, 2007b, 2004; Kortbeek et
al., 2009; Lake et al., 2010; Praet et al., 2009; Reij et al., 2009;
Torgerson et al., 2008; Van Lier et al., 2007) included sequelae in
the YLD calculations. The number of cases that developed sequelae
was calculated using probabilities derived from literature and
sometimes supplemented by data from disease registries and/or
specific studies. It should be noted that, between studies that esti-
mated burden of disease of the same agent, there were differences
regarding the sequelae that were included. Some studies on the
burden of Campylobacter and Salmonella included post-infectious
irritable bowel syndrome (Gkogka et al., 2011; Haagsma et al.,
2008; Havelaar et al., 2012), whereas other studies did not take
this sequela into account (Havelaar et al., 2000; Lake et al., 2010).
Comorbidity adjustment—Two studies that adjusted for comor-
bidity applied a reduced life span in case of co-occurrence of liste-
riosis and other diseases (Havelaar et al., 2012; Verhoef et al.,
2012). Mathers et al. corrected for comorbidity by adjusting the
disability weights for common co-occurring disease (Mathers et
al., 2007).
3) Which methods were used to handle uncertainty?
Each burden of disease study contains uncertainty as a result of
possible imprecision in the model parameters that are used (pa-
rameter uncertainty), methodological controversy (model uncer-
tainty) or systematic uncertainty and uncertainty due to a lack of
data (structural uncertainty (Bilcke et al., 2011). Model uncertain-
ty reflects the uncertainty around methodological choices and it
can be evaluated by sensitivity analysis, which tests whether plau-
sible changes in assumptions or model choices affect the results of
the analysis (Murray and Lopez, 1996). Several studies (n = 7)
performed such a sensitivity analysis, e.g. to evaluate the effect of in-
cluding discounting and of different discount rates (Havelaar et al.,
2012) or different life tables (Gkogka et al., 2011).
Structural uncertainty can be evaluated by scenario analysis. In a
scenario analysis only one parameter will be changed at time,
whereas all other parameters remain unchanged. Several studies ap-
plied scenario analysis, for instance to assess the effect of the inclu-
sion of a certain sequela the calculation of the burden of disease
(Havelaar et al., 2012), to estimate the long-term effect of diarrhoeal
disease in children aged under 4 (Guerrant et al., 2002) or to analyze
different prevalence rates or exposure (Praet et al., 2009; Pruss et al.,
2002).
Parameter uncertainty can be specified with a probability distribu-
tion. Almost all studies analyzed the effect of parameter uncertainty
with probabilistic analysis using Monte Carlo simulation.
4. Discussion
We systematically reviewed 24 burden of disease studies using
the DALY approach and performed a quality assessment of the meth-
odology used. The majority of the included studies comprised of
agent-based foodborne burden of disease studies (75%). We found
that studies generally followed the GBD 1996 approach, which con-
sists of using the incidence-based approach, GBD disability weights
Table 2
Agent-based BoD studies related to foodborne disease (n = 19): data sources used, quality of the data and extrapolation for YLD.
Author, Year Agent Starting point Data used Extra-polation Assumptions Uncertainty
Budke et al. (2004) Tibet Echinococcosis Cohort data Mortality: assumptions Morbidity:
prevalence data Duration: assumptions
Yes Progression, duration
and fatality
Uncertainty of disabilityweights and
prevalence rates was modelled
Fewtrell et al. (2004)
Global
Lead Exposure data Mortality and morbidity:
data on exposure
Yes Sample exposure is equal
to regional exposure
No
Fewtrell et al. (2005)
Global
Arsenicum Exposure data Mortality:– Morbidity: exposure and
dose–response from literature
Yes Age distribution of exposed equal
to age distribution of the country
population; duration of 10 years
Three prevalence scenarios
were formulated and uncertainty
was then modelled
Furst et al. (2012) Global Trematodes Literature review Mortality: literature Morbidity:
literature Duration: literature
Yes No remission Uncertainty was analyzed;
details are not available
Gkogka et al. (2011)
Greece
Botulism, Bruccelosis,
Campylobacteriosis, EHEC,
Leptospirosis, Listeriosis,
Salmonellosis, Shigellosis,
Amebiasis, Cryptosporidiosis,
Echinococcosis, Giardiasis,
Toxoplasmosis, Hepatitis A
Laboratory confirmed cases Mortality: Case-fatality ratios
Morbidity: Laboratory confirmed
cases Duration: Literature
Yes Multipliers for seriousness
of illness
Uncertainty caused by
underreporting and food
attribution were taken
into account
Haagsma et al. (2008)
The Netherlands
Norovirus, rotavirus, Campylobacter spp.,
Salmonella spp., and STEC O157
Cohort data Mortality: literature Morbidity:
community-based and gp-based
cohort data Duration: literature
Yes Probabilities of death and
development of sequelae
Uncertainty of incidence
was modelled
Havelaar et al. (2000)
The Netherlands
Campylobacter spp. Cohort data Mortality: literature Morbidity: outbreak
reports, laboratory reports, GP-based
surveillance and population-based
surveys Duration: literature
Yes Probabilities of death and
development of sequelae
Uncertainty of incidence
was modelled
Havelaar et al. (2004)
The Netherlands
STEC O157 Cohort data Mortality: literature Morbidity:
community-based and GP-based
cohort data Duration: literature
Yes Probabilities of death and
development of sequelae
Uncertainty of incidence
was modelled
Havelaar et al.
(2007b)
The Netherlands
Toxoplasma gondii (congenital only) Cohort data Mortality: literature Morbidity:
prospective cohort data and
cross-sectional sero-prevalence
data Duration: literature
Yes Probabilities of foetal loss and
development of sequelae
Uncertainty of incidence
was modelled
Havelaar et al. (2012)
The Netherlands
Campylobacter, Salmonella, norovirus,
rotavirus, STEC O157, Staphylococcus
aureus, Bacillus cereus, Clostridium
perfringens, Giardia lamblia, Cryptosporidium
parvum, Listeria monocytogenes, Hepatitis
A virus, Hepatitis E virus
Cohort data, laboratory
confirmed cases
Mortality: literature Morbidity:
community-based and GP-based
cohort study and laboratory surveillance
system data Duration: literature
Yes Probabilities of death and
sequelae
Uncertainty of incidence
was modelled
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Kortbeek et al. (2009)
The Netherlands
Toxoplasma gondii (congenital only) Cohort data Mortality: literature Morbidity: data
from cohort study Duration: literature
Yes Probabilities of foetal loss and
development of sequelae
To account for uncertainty, low
values, most likely values and
high values were used for the
parameters
Lake et al. (2010)
New Zealand
Campylobacteriosis, Salmonellosis,
Listeriosis, STEC infection,
Yersiniosis, norovirus infection
Laboratory confirmed
cases
Mortality: mortality data from health
services registries Morbidity:
surveillance data Duration: literature
Yes Probabilities of hospitalizations,
and sequelae; FBD attributions
Uncertainty of the incidence
estimates was modelled
Lokuge et al. (2004)
Bangladesh
Arsenicum Exposure data Mortality and morbidity: exposure and
dose–response from literature
Yes Sample exposure is equal to
regional exposure
No
Praet et al. (2009)
Cameroon
Taenia solium Survey data Mortality: assumptions Morbidity:
prevalence data from population surveys
Durations: assumptions
Yes Attribution to NCC, hospitaliza-
tion, outpatient treatment, cases
in the population, mortality and
durations
Three prevalence scenarios
were formulated and
uncertainty was then modelled
Reij et al. (2009)
The Netherlands
Cronobacter spp. Exposure data Mortality: literature Morbidity: exposure
and dose–response Duration: European
Hospital Morbidity Database
Yes Exposure, dose–response
and underreporting factor
Uncertainty in exposure and
dose response was modelled
Torgerson et al. (2008)
Switzerland
Human alveolar echinococcosis Laboratory confirmed cases Mortality: Survival analysis Morbidity:
Laboratory confirmed cases Duration:
Survival analysis
No Excess hazard compared to the
Swiss population norms was
assumed to be due Human
alveolar echinococcosis
Parameter uncertainty and
scenario analysis was performed
Valent et al. (2004)
Europe
Lead Exposure data Mortality:– Morbidity: data on
exposure and literature
Yes Sample exposure is equal to
regional exposure; lead
prevention activities
reduce blood lead levels by 8%
Three incidence scenarios were
formulated and uncertainty
was then modelled
Van Lier et al. (2007)
The Netherlands
Influenza, measles, HIV,
Campylobacteriosis, EHEC infection,
Salmonellosis, Tuberculosis
Laboratory confirmed cases Mortality: mortality data Eurostat
Morbidity: surveillance data Eurostat
Duration: literature
No No mortality reported, then
mortality is zero; probabilities for
the development of sequelae
For some diseases the effect of
underreporting was explored
by scenario analysis
Verhoef et al. (2012)
The Netherlands
Norovirus Cohort data
(community-acquired
cases), laboratory confirmed
cases (outbreak cases)
Mortality: case-fatality ratios Morbidity:
cohort data, registry for hospitalization,
laboratory surveillance data of hospitalized
cases and passive laboratory surveillance
Duration: literature
Yes Proportion outbreak cases that
visit a GP
Uncertainty of incidence was
modelled
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(79%) used the incidence based approach. Almost half of the studies
used age-weighting (42%), whereas more than 50% of the studies
used discounting. Two thirds of the foodborne burden of disease stud-
ies (67%) analyzed the effect of uncertainty as a result of possible im-
precision in the parameter values.Laboratory confirmed cases 
Extrapolate cases to other levels of 
the surveillance pyramid
Incidence of illness 
Data from cohort or cross sectional 
study
(e.g. seroprevalence, positive stool samples or 
particular health outcome)
Estimate severity levels of the 
health outcomes
Extrapolate cases to total 
population
Prevalence of illness
Incidence of illness
a
b
Fig. 3. Four approaches to estimate incidence, each using a different type of information as a
sectional data to incidence. C. From syndrome surveillance or survey data to incidence. D. F4.1. Epidemiological data
To assess the burden of disease of a particular agent requires high
quality data. The diverse range of data sources, literature research
and/or expert opinion data that are used pointed out that incidence
and prevalence data regarding foodborne disease are particularlyCollect data regarding the health 
case system (e.g. coverage of surveillance
system, feacal sample testing, reporting etc)
Assess scaling factors
Assess scaling factors
(based on e.g. regional coverage, age composition of
cohort, etc)
starting point. A. From laboratory-confirmed cases to incidence. B. From cohort or cross
rom exposure data to incidence.
Syndrome surveillance or survey 
data
Estimate severity levels of the 
health outcome(s)
Extrapolate exposure to total 
population
Assess scaling factors
(based on e.g. sample size, size of population, etc)
Prevalence of illness
Incidence of illness
Estimate proportion associated with 
agent 
Assess attributable fraction
(based on e.g. literature etc)
c
Fig. 3 (continued).
43J.A. Haagsma et al. / International Journal of Food Microbiology 166 (2013) 34–47hard to come by. With regards to the foodborne disease model, most
of the included studies used the agent-based approach. By nature of
its setup the agent-based approach allows an estimate of the burden
of disease due to a certain agent. The advantage of this approach is
that this estimate includes both acute health effects as well as sequel-
ae, even if these are delayed.
Regarding the data sources four approaches to arrive at incidence
data could be discerned, each using a distinct type of information as a
starting point, e.g. data from laboratory surveillance or exposure data.
Dependent on the type of information that was used as a starting
point, data was extrapolated to other levels of the surveillance pyra-
mid or geographically regional data was extrapolated to the whole
population using scaling factors. These scaling factors were based on
surveys, expert opinion or assumptions. In many cases, the informa-
tion for the scaling factors was limited or crude, which raises ques-
tions about the validity of the extrapolations. Nonetheless, many
studies examined structural uncertainty of assumptions by means of
scenario analysis.
The data quality and data gaps were also highly dependent on the
information that was used as a starting point. Frequently found data
gaps concerned severity distribution of the health outcomes, propor-
tion of cases that develop sequelae and mortality rates. Moreover,
studies were sometimes restricted to one or two health outcomesrather than all health outcomes that may be caused by the agent. In
case of missing data, assumptions were made which were often de-
rived from literature or based on expert opinion.4.2. Methodological choices for DALY calculations
There are several applications for burden of disease studies, ranging
from comparison of diseases in the same population and comparison
of the overall health status between two or more populations
through analysis of the benefits of health interventions for use in
cost-effectiveness studies and provision of information to assist in set-
ting priorities for health planning, public health programs and research
(Mathers et al., 2001). Model choices affect the outcomes of the analy-
sis, yet the importance of this effect is dependent on the application of
the study. If the ultimate goal of the study is risk ranking of foodborne
diseases, then model choices are less important; it is their consistency
of application that is important. If the burden estimates are to be com-
pared with those for other diseases, or across regions or countries
then the model choices are more important.
The calculation of the morbidity component of the burden of dis-
ease, expressed in YLD, depends highly on the specific model being
applied and the type of data underlying this model. Variation in
Fig. 3 (continued).
44 J.A. Haagsma et al. / International Journal of Food Microbiology 166 (2013) 34–47methodological choices included the disability weights and applica-
tion of age-weighting and discounting.
Most studies used the GBD disability weights, in many cases
supplemented by disability weights from the Dutch disability weights
set. The GBD disability weights cover a wider range of conditions than
covered by Dutch disability weights, but are generally less specific in
terms of the disease and sequelae categories to which they refer. Sev-
eral studies reported that there were no disability weights available
for particular health outcomes. In these cases, disability weights of
health outcomes with similar health effects were used. For other
health outcomes, disability weights from different sets are available.
To ensure a uniform method to assess burden of foodborne disease,
it should be decided which set of disability weights is preferred for
foodborne burden of disease studies. Also, missing disability weights
for health outcomes caused by foodborne agents should be identified
and proxy-disability weights should be proposed (e.g. adopt disability
weights from other sets of disability weights, or use a disability
weight of a disease with similar symptoms and impact).
In the original GBD study discounting and age-weighting are ap-
plied. However, both age-weighting and discounting have been dis-
puted. The drawback of age-weighting is that it has been disputed
on equity grounds (higher weights are assigned to people between
18 and 55 years old), the absence of empirical foundation andvalidation, and because the age weights do not convey actual social
values because this practice is controversial (Anand and Hanson,
1997; Johanneson and Johansson, 1997).
Discounting has been disputed because its application results in a
lower efficiency of prevention programs, whereas not discounting, or
the use of a low discount rate—lower than the discount rate used for
the costs—favor preventive measures due to benefit in the far future
(Drummond et al., 1997). This discussion is reflected in different
choices to use discounting and age-weighting between the included
studies in our review. We recommend reporting both discounted
and undiscounted DALYs.
When focusing on a single cause of disease in a population, it
should be noted that foodborne agents may be linked to health out-
comes with have multiple causative agents and risk factors. In these
cases it is important to define envelopes by estimating total mortality
and morbidity for a population/country. Defining mortality and/or
morbidity envelopes in burden of foodborne disease studies ensures
that the cause-specific estimates add to the total mortality and mor-
bidity by age and sex and avoids systematic underestimation or dou-
ble counting of deaths and morbidity (Murray and Lopez, 1996).
This is particularly important because the majority of studies used
case-fatality ratios rather than vital registration data to calculate
mortality and an extrapolation of available disease data in order to
Table 3
Methods used to calculate YLL and YLD in burden of disease studies related to foodborne disease.
Author, year General burden of disease methods YLL methodology YLD methodology
Incidence or
prevalence based
approach
Agent, outcome or
risk factor-based?
Type of
agent
Age
weighting
Discounting Were missing
values handled?
Sensitivity/
uncertainty
analysis
Which life tables used? Disability
weights
Sequelae
include?
Distribution
by severity?
Adjustment for
comorbidity
GBD approach Incidence Outcome-based n.a. Y Y Y Y Standard West 25 (males)
and 26 (females)
GBD Y N N
Budke et al. (2004) Incidence Agent-based Parasitic Y Y Y Y Standard West 25 (females)
and 26 (males)
GBD, DDW Y Y N
Fewtrell et al. (2004) Incidence Agent-based Chemical N N – – – – – – –
Fewtrell et al. (2005) Prevalence Agent-based Chemical Y Y n.a. Y n.a. n.a. n.a. Y N
Furst et al. (2012) Prevalence Agent-based Parasitic N N n.a. Y n.a. GBD Y n.a. N
Gkogka et al. (2011) Incidence Agent-based Enteric, parasitic N N n.a. Y Standard life tables for Greece GBD, DDW Y Y N
Guerrant et al. (2002) Incidence Outcome-based – Y Y n.a. n.a. n.a. GBD Y n.a. N
Haagsma et al. (2008) Incidence Agent-based Enteric N Y Y Y Standard life tables for
Netherlands
DDW Y Y N
Havelaar et al. (2000) Incidence Agent-based Enteric N Y Y Y Standard West 25 (females)
and 26 (males)
GBD, EQ5D Y Y N
Havelaar et al. (2004) Incidence Agent-based Enteric N Y Y Y Standard life tables for
Netherlands
GBD, DDW Y Y Y
Havelaar et al.
(2007b)
Incidence Agent-based Parasitic N Y n.a. Y Standard West 25 (females)
and 26 (males)
DDW Y Y N
Havelaar et al. (2012) Incidence Agent-based Enteric, parasitic N Y Y Y Standard West 25 (females)
and 26 (males)
GBD, DDW Y Y Y
Kortbeek et al. (2009) Incidence Agent-based Parasitic N n.a. n.a. Y Standard life tables for
Netherlands
n.a. Y N N
Lake et al. (2010) Incidence Agent-based Enteric N Y n.a. Y Standard life tables for New
Zealand
DDW, GBD Y Y N
Lewin et al. (2007) Incidence Risk factor-based – N N – – – – – – –
Lokuge et al. (2004) Incidence Agent-based Chemical Y Y n.a. n.a. n.a. – – – –
Mathers et al. (2007) Incidence Outcome-based – Y Y n.a. n.a. Standard West 25 (females)
and 26 (males)
GBD Y n.a. Y
Nafar et al. (2008) Incidence Outcome-based – Y Y Y n.a. Standard life tables for Iran Iranian DW – n.a. N
Praet et al. (2009) Incidence Agent-based Parasitic Y Y n.a. Y Standard West 25 (females)
and 26 (males)
GBD Y N N
Pruss et al. (2002) Incidence Risk factor-based – Y Y n.a. n.a. Standard West 25 (females)
and 26 (males)
GBD n.a. N N
Reij et al. (2009) Incidence Agent-based Enteric N N n.a. Y Standard West 25 (females)
and 26 (males)
GBD Y N N
Torgerson et al. (2008) Incidence Agent-based Parasitic Y Y Y Y Swiss life tables DDW Y Y N
Valent et al. (2004) Incidence Chemical Chemical Y Y n.a. Y n.a. DDW, GBD N n.a. N
Van Lier et al. (2007) Incidence Agent-based Enteric N N n.a. Y Standard West 25 (females)
and 26 (males)
GBD Y N N
Verhoef et al. (2012) Incidence Agent-based Enteric N Y n.a. Y Standard West 25 (females)
and 26 (males)
DDW N Y Y
n.a. = not available,– = not applicable.
Abbreviations disability weights: Disability weights: GBD1990/GBD 1996 = Global Burden of Disease disability weights 1990, GBD2000 = Global Burden of Disease disability weights 1990 supplemented with Dutch Disability weighs, DDW
= Dutch Disability weights, EQ5Ddw = EQ5D disability weights.
45
J.A
.H
aagsm
a
et
al./
InternationalJournalofFood
M
icrobiology
166
(2013)
34
–47
46 J.A. Haagsma et al. / International Journal of Food Microbiology 166 (2013) 34–47assess the incidence in the population. Strikingly, however, none of
the burden of disease studies mentioned the use of a mortality
envelope.
An aspect related to mortality due to foodborne diseases is the in-
clusion of stillbirth and fetal loss in disease burden estimates. Several
foodborne agents, such as parasites (e.g. Toxoplasma gondii), enteric
pathogens (e.g. Listeria monocytogenes) and chemical contaminants
(e.g. arsenic exposure) may cause stillbirth and/or fetal death. The
current situation is that a baby who dies just after birth counts in
the GBD metrics. However, a baby who dies in the third trimester
or during labor does not count, because of ethical issues and for
practical reasons (Bhutta et al., 2011; Lawn et al., 2011; Murray
and Lopez, 1996; Pattinson et al., 2011). Therefore, currently there
are no established methods to account for fetal loss. A major practi-
cal problem is that stillbirths are not routinely recorded in surveys.
Furthermore, if data are recorded they are often reported as perina-
tal mortality, which reduces visibility and might obfuscate differ-
ences in reporting and systematic misclassification (Lawn et al.,
2011; Pattinson et al., 2011). Jamison et al. have performed a sensi-
tivity analysis of an approach that incorporates stillbirths in the
GBD estimates (Jamison et al., 2006). Havelaar et al. and Kortbeek
et al. included losses of a viable fetus (more than24 weeks in The
Netherlands) in their estimates of the burden of congenital toxo-
plasmosis (Havelaar et al., 2007b; Kortbeek et al., 2009).
4.3. Uncertainty
The precision of DALY estimates is not quantifiable in the usual
statistical sense of deriving a confidence interval, because the preci-
sion varies across diseases and depends highly on the specific ap-
proach being applied and the type of data underlying this model.
Uncertainty in burden of disease studies may result from data uncer-
tainties, such as statistical uncertainty due to small sample size, sys-
tematic uncertainty or lack of data. This uncertainty is dealt with by
uncertainty analysis, which tests whether plausible changes in values
of the main variables affect the results of the analysis. These analyses
show how, for instance, the effect of uncertainty in the disability
weights and/or uncertainty in the incidence data.
5. Conclusions
Accurate quantification of the population burden of disease is im-
portant for resource allocation and the identification of important
prevention priorities. However, a major challenge that is met when
performing foodborne burden of disease studies is lack of available
data. Our review showed that a wide variety of sources were used
to assess mortality, morbidity and disability and that profound statis-
tical modelling was often needed to extrapolate the data to other
levels of the surveillance pyramid and/or the whole population
under study. Secondly, we found that large differences existed in bur-
den of disease methodology, although most studies used the
incidence-based approach. This dominance of the incidence-based
approach is strongly related to the perspective of the study. Most
studies used an agent-based approach to assess the health impact of
a particular agent and this perspective requires an incidence-based
approach. The methodological choices that are made and the impor-
tance of the effect of methodological choices on the burden of
disease estimates are dependent on the application of the study.
Furthermore, our review showed that the majority of the included
studies analyzed the effect of model, structural and/or parameter
uncertainty.
Awareness of epidemiological and methodological rigor between
burden of disease studies using the DALY approach is a critical priority
for advancing burden of disease studies. Harmonization of themethod-
ology that is used, high quality data and advancedmodeling techniques
can enlarge the detection of real variation in DALY outcomes betweenpopulations or over time. This harmonization can be achieved by iden-
tifying substantial data gaps and uncertainty and establish which se-
quelae of foodborne disease agents should be included in burden of
disease calculations.
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